Bromopride

Bromopride

Clinical data
AHFS/Drugs.com	International Drug Names
Routes of administration	Oral, IM, IV
ATC code	A03FA04 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability	50 to 75% (oral) 78% (intramuscular)
Protein binding	40%
Metabolism	Hepatic
Elimination half-life	4 to 5 hours
Excretion	Renal, 10 to 14% unchanged
Identifiers
IUPAC name 4-amino-5-bromo-N-[2-(diethylamino)ethyl]-2-methoxybenzamide
CAS Number	4093-35-0 N
PubChem CID	2446
DrugBank	DB09018 N
ChemSpider	2352 Y
UNII	75473V2YZK
KEGG	D07101 Y
ChEMBL	ChEMBL399510 Y
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C14H22BrN3O2
Molar mass	344.248 g/mol
3D model (JSmol)	Interactive image
SMILES Brc1cc(c(OC)cc1N)C(=O)NCCN(CC)CC
InChI InChI=1S/C14H22BrN3O2/c1-4-18(5-2)7-6-17-14(19)10-8-11(15)12(16)9-13(10)20-3/h8-9H,4-7,16H2,1-3H3,(H,17,19) Y Key:GIYAQDDTCWHPPL-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

WikiDoc Resources for Bromopride
Articles
Most recent articles on Bromopride Most cited articles on Bromopride Review articles on Bromopride Articles on Bromopride in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Bromopride Images of Bromopride Photos of Bromopride Podcasts & MP3s on Bromopride Videos on Bromopride
Evidence Based Medicine
Cochrane Collaboration on Bromopride Bandolier on Bromopride TRIP on Bromopride
Clinical Trials
Ongoing Trials on Bromopride at Clinical Trials.gov Trial results on Bromopride Clinical Trials on Bromopride at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Bromopride NICE Guidance on Bromopride NHS PRODIGY Guidance FDA on Bromopride CDC on Bromopride
Books
Books on Bromopride
News
Bromopride in the news Be alerted to news on Bromopride News trends on Bromopride
Commentary
Blogs on Bromopride
Definitions
Definitions of Bromopride
Patient Resources / Community
Patient resources on Bromopride Discussion groups on Bromopride Patient Handouts on Bromopride Directions to Hospitals Treating Bromopride Risk calculators and risk factors for Bromopride
Healthcare Provider Resources
Symptoms of Bromopride Causes & Risk Factors for Bromopride Diagnostic studies for Bromopride Treatment of Bromopride
Continuing Medical Education (CME)
CME Programs on Bromopride
International
Bromopride en Espanol Bromopride en Francais
Business
Bromopride in the Marketplace Patents on Bromopride
Experimental / Informatics
List of terms related to Bromopride

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Bromopride (INN) is a dopamine antagonist with prokinetic properties widely used as an antiemetic, closely related to metoclopramide. It is not available in the United States.

Bromopride appears to be safe and effective for use in pregnancy.

Indications

Bromopride is indicated in the treatment of nausea and vomiting, including postoperative nausea and vomiting (PONV); gastroesophageal reflux disease (GERD/GORD); and as preparation for endoscopy and radiographic studies of the gastrointestinal tract. The manufacturer also claims it is valuable in, among other indications, hiccups and gastrointestinal adverse effects of radiation therapy.

Adverse effects

Bromopride is generally well tolerated; the most common adverse effects of its use are somnolence and fatigue. Bromopride may rarely cause extrapyramidal symptoms and, as with metoclopramide, may increase prolactin levels.

Chemistry

Bromopride is a substituted benzamide, closely related to metoclopramide. It is identical to metoclopramide except for the presence of a bromine atom where metoclopramide has a chlorine substituent.

Availability

Bromopride is not available in the United States or the United Kingdom. It is marketed in Brazil by Sanofi-Synthélabo under the trade name 'Digesan, by LIBBS under the name Plamet, and as a generic drug.